JP6514712B2 - ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用 - Google Patents

ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用 Download PDF

Info

Publication number
JP6514712B2
JP6514712B2 JP2016552698A JP2016552698A JP6514712B2 JP 6514712 B2 JP6514712 B2 JP 6514712B2 JP 2016552698 A JP2016552698 A JP 2016552698A JP 2016552698 A JP2016552698 A JP 2016552698A JP 6514712 B2 JP6514712 B2 JP 6514712B2
Authority
JP
Japan
Prior art keywords
iii
formula
tetraazabicyclo
methyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016552698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538337A5 (https=
JP2016538337A (ja
Inventor
トリピエール，ラファエル
ハリメ，ザカリア
Original Assignee
ユニバーシテ デ ブルターニュ オキシデンタル
ユニバーシテ デ ブルターニュ オキシデンタル
センター ナショナル デ ラ リシェルシェ サイエンティフィック（シーエヌアールエス）
センター ナショナル デ ラ リシェルシェ サイエンティフィック（シーエヌアールエス）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシテ デ ブルターニュ オキシデンタル, ユニバーシテ デ ブルターニュ オキシデンタル, センター ナショナル デ ラ リシェルシェ サイエンティフィック（シーエヌアールエス）, センター ナショナル デ ラ リシェルシェ サイエンティフィック（シーエヌアールエス） filed Critical ユニバーシテ デ ブルターニュ オキシデンタル
Publication of JP2016538337A publication Critical patent/JP2016538337A/ja
Publication of JP2016538337A5 publication Critical patent/JP2016538337A5/ja
Application granted granted Critical
Publication of JP6514712B2 publication Critical patent/JP6514712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Removal Of Specific Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2016552698A 2013-11-12 2014-11-12 ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用 Active JP6514712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192597.6A EP2871186B1 (en) 2013-11-12 2013-11-12 Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof
EP13192597.6 2013-11-12
PCT/EP2014/074415 WO2015071334A1 (en) 2013-11-12 2014-11-12 Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof

Publications (3)

Publication Number Publication Date
JP2016538337A JP2016538337A (ja) 2016-12-08
JP2016538337A5 JP2016538337A5 (https=) 2017-12-14
JP6514712B2 true JP6514712B2 (ja) 2019-05-15

Family

ID=49582592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552698A Active JP6514712B2 (ja) 2013-11-12 2014-11-12 ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用

Country Status (6)

Country Link
US (1) US10434199B2 (https=)
EP (2) EP2871186B1 (https=)
JP (1) JP6514712B2 (https=)
CA (1) CA2930274C (https=)
ES (1) ES2657704T3 (https=)
WO (1) WO2015071334A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774803A1 (en) 2018-03-30 2021-02-17 Centre national de la recherche scientifique Pyclen-based macrocyclic ligands, chelates thereof and uses thereof
WO2025153023A1 (en) * 2024-01-17 2025-07-24 C Ray Therapeutics (Shanghai) Co., Ltd. Fibroblast activation protein ligands and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0955044B1 (en) 1995-06-26 2005-11-16 Chelator LLC Method of inhibiting bacterial or fungal growth using a complexing agent
KR101199570B1 (ko) * 2009-09-09 2012-11-13 경북대학교 산학협력단 신규한 테트라아자 거대고리 화합물, 제조방법 및 그 용도
WO2012037648A1 (en) * 2010-09-20 2012-03-29 Nordion (Canada) Inc. Process for chelating copper ions using cb-te2a bifunctional chelate
FR2982611B1 (fr) 2011-11-16 2014-01-03 Univ Bretagne Occidentale Procedes de preparation de composes tetraazacycloalcanes fonctionnels a l'aide d'un compose cyclique bisaminal particulier.

Also Published As

Publication number Publication date
US20160287733A1 (en) 2016-10-06
ES2657704T3 (es) 2018-03-06
EP3068787B1 (en) 2017-11-01
WO2015071334A1 (en) 2015-05-21
EP3068787A1 (en) 2016-09-21
EP2871186B1 (en) 2016-09-21
CA2930274C (en) 2021-10-26
US10434199B2 (en) 2019-10-08
EP2871186A1 (en) 2015-05-13
CA2930274A1 (en) 2015-05-21
JP2016538337A (ja) 2016-12-08

Similar Documents

Publication Publication Date Title
Thiele et al. Implementing f-block metal ions in medicine: tuning the size selectivity of expanded macrocycles
Wadas et al. Copper chelation chemistry and its role in copper radiopharmaceuticals
US12269837B2 (en) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
US10842893B2 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
Kostelnik et al. Phosphonate chelators for medicinal metal ions
Joaqui-Joaqui et al. Catechol-based functionalizable ligands for gallium-68 positron emission tomography imaging
EP3007732B1 (en) Bifunctional chelating agents based on the 1,4-diazepine scaffold (daza) for non-invasive molecular imaging
JP6525968B2 (ja) トランス−ジ−ｎ−ピコリネートテトラアザシクロアルカンベースの鉛（ｉｉ）およびビスマス（ｉｉｉ）のキレート
JP6514712B2 (ja) ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用
KR101191649B1 (ko) 이작용기성 테트라아자 거대고리 화합물의 제조방법 및 용도
EP4273142A1 (en) Picolinate cyclam palladium chelates and uses thereof
US12419977B2 (en) Radiopharmaceuticals
RU2846763C1 (ru) Способы мечения радиоактивными изотопами psma-связывающих лигандов и наборы для их осуществления
Hoerres Complexation of rhenium-186 and technetium-99m tricarbonyl cores with 1, 4, 7-triazacyclononane based chelators for radiopharmaceutical applications
Jowanaridhi Development of Zirconium-89 Chelators for Use in Positron Emission Tomography Imaging
Brown The design, synthesis, and evaluation of radiopharmaceuticals for actinium-225
WO2025030160A1 (en) Chelating compounds and methods of uses thereof
Rück Synthesis and evaluation of novel picolinic acid-based bispidine ligands and their metal complexes for the application in nuclear medicine
Boros Acyclic chelates for imaging with radiometals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20171106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180131

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190412

R150 Certificate of patent or registration of utility model

Ref document number: 6514712

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250